Document Detail

An analysis of the "Effect of Olibra: a 12-week randomized control trial and a review of earlier studies".
MedLine Citation:
PMID:  22768903     Owner:  NLM     Status:  MEDLINE    
Nutrients affect hunger and satiety. However, food structure, in particular that of emulsions, may also affect the body's satiety mechanisms. Olibra™ is a fat emulsion, a mixture of fractionated palm oil and fractionated oat oil manufactured by Lipid Technologies Provider AB, Sweden, which affects hunger sensation. However, up to now, no data have shown convincingly that reduced appetite or hunger sensations induced by Olibra lead, in the long run, to a significant and clinically relevant reduction in body mass. To clearly demonstrate a cause-and-effect relationship of Olibra to weight loss, it seems that longer studies with strict control of energy intake and nutrient composition, as well as control of energy expenditure by exercise, are needed.
Martina Heer
Related Documents :
22874653 - A school-based supplementary food programme in rural kenya did not reduce children's in...
22443953 - Influence of sward structure on daily intake and foraging behaviour by horses.
20492233 - Modeling of the humidity effects on the oxygen absorption by iron-based scavengers.
Publication Detail:
Type:  Comment; Journal Article     Date:  2012-05-01
Journal Detail:
Title:  Journal of diabetes science and technology     Volume:  6     ISSN:  1932-2968     ISO Abbreviation:  J Diabetes Sci Technol     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-07-09     Completed Date:  2013-07-05     Revised Date:  2013-07-12    
Medline Journal Info:
Nlm Unique ID:  101306166     Medline TA:  J Diabetes Sci Technol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  709-11     Citation Subset:  IM    
Copyright Information:
© 2012 Diabetes Technology Society.
Profil Institute for Metabolic Research GmbH, Neuss, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Obesity Agents / therapeutic use*
Dietary Fats / therapeutic use*
Emulsions / therapeutic use*
Obesity / drug therapy*
Reg. No./Substance:
0/Anti-Obesity Agents; 0/Dietary Fats; 0/Emulsions
Comment On:
J Diabetes Sci Technol. 2012 May;6(3):695-708   [PMID:  22768902 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Efficacy of Olibra: a 12-week randomized controlled trial and a review of earlier studies.
Next Document:  The challenges of measuring glycemic variability.